Showing 741-760 of 8875 for: Cochrane Systematic Reviews Back
- Antioxidants for female subfertility
Cochrane Systematic Reviews, 27-Aug-2020
A couple may be considered to have fertility problems if they have been trying to conceive for over a year with no success. This may affect up to a quarter of all couples planning a child. It is estimated that for 40% to 50% of couples, subfertility may r
- Antioxidants for male subfertility
Cochrane Systematic Reviews, 4-May-2022
The inability to have children affects 10% to 15% of couples worldwide. A male factor is estimated to account for up to half of the infertility cases with between 25% to 87% of male subfertility considered to be due to the effect of oxidative stress. Oral
- Antioxidants for pain in chronic pancreatitis
Cochrane Systematic Reviews, 5-Aug-2014
Reduced intake and absorption of antioxidants due to pain and malabsorption are probable causes of the lower levels of antioxidants observed in patients with chronic pancreatitis (CP). Improving the status of antioxidants might be effective in slowing the
- Antioxidants for preventing and reducing muscle soreness after exercise
Cochrane Systematic Reviews, 14-Dec-2017
Muscle soreness typically occurs after intense exercise, unaccustomed exercise or actions that involve eccentric contractions where the muscle lengthens while under tension. It peaks between 24 and 72 hours after the initial bout of exercise. Many people
- Antioxidants for preventing pre-eclampsia
Cochrane Systematic Reviews, 16-May-2012
Oxidative stress has been proposed as a key factor involved in the development of pre-eclampsia. Supplementing women with antioxidants during pregnancy may help to counteract oxidative stress and thereby prevent or delay the onset of pre-eclampsia.
- Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline
Cochrane Systematic Reviews, 1-Dec-2021
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder characterised by progressive muscle weakness beginning in early childhood. Respiratory failure and weak cough develop in all patients as a consequence of muscle weakness leading to a risk
- Antiplatelet agents and anticoagulants for hypertension
Cochrane Systematic Reviews, 28-Jul-2022
The main complications of elevated systemic blood pressure (BP), coronary heart disease, ischaemic stroke, and peripheral vascular disease, are related to thrombosis rather than haemorrhage. Therefore, it is important to investigate if antithrombotic ther
- Antiplatelet agents for chronic kidney disease
Cochrane Systematic Reviews, 28-Feb-2022
Antiplatelet agents are widely used to prevent cardiovascular events. The risks and benefits of antiplatelet agents may be different in people with chronic kidney disease (CKD) for whom occlusive atherosclerotic events are less prevalent, and bleeding haz
- Antiplatelet agents for intermittent claudication
Cochrane Systematic Reviews, 3-Oct-2011
Peripheral arterial disease (PAD) is common and is a marker of systemic atherosclerosis. Patients with symptoms of intermittent claudication (IC) are at increased risk of cardiovascular events (myocardial infarction (MI) and stroke) and of both cardiovasc
- Antiplatelet agents for preventing and treating pre-eclampsia
Cochrane Systematic Reviews, 5-Nov-2008
Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a platelet-derived vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses
- Antiplatelet agents for preventing pre‐eclampsia and its complications
Cochrane Systematic Reviews, 30-Oct-2019
Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that antiplatele
- Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery
Cochrane Systematic Reviews, 19-Feb-2015
Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or prosthetic (artificial) graft. A number of factors inf
- Antiplatelet agents for the treatment of deep venous thrombosis
Cochrane Systematic Reviews, 25-Jul-2022
Antiplatelet agents may be useful for the treatment of deep venous thrombosis (DVT) when used in addition to best medical practice (BMP), which includes anticoagulation, compression stockings, and clinical care such as physical exercise, skin hydration, e
- Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies
Cochrane Systematic Reviews, 13-Jul-2018
Antiphospholipid syndrome (APS) is an autoimmune disease characterised by the presence of antiphospholipid (aPL) antibodies that have prothrombotic activity. Antiphospholipid antibodies are associated with an increased risk of pregnancy complications (rec
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Cochrane Systematic Reviews, 12-Oct-2020
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial or venous thrombosis (or both), and/or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The prevalence of APS is estimated at 40
- Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment
Cochrane Systematic Reviews, 15-Aug-2012
Peripheral arterial disease (PAD) is frequently treated by balloon angioplasty. Restenosis/reocclusion of the dilated segments occurs often, depending on length of occlusion, lower leg outflow, stage of disease and presence of cardiovascular risk factors.
- Antiplatelet and anticoagulation for patients with prosthetic heart valves
Cochrane Systematic Reviews, 9-Jul-2013
Patients with prosthetic heart valves are at increased risk for valve thrombosis and arterial thromboembolism. Oral anticoagulation alone, or the addition of antiplatelet drugs, has been used to minimise this risk. An important issue is the effectiveness
- Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia
Cochrane Systematic Reviews, 30-Apr-2013
Polycythaemia vera and essential thrombocythaemia are chronic Philadelphia-negative myeloproliferative neoplasms that increase the risk of arterial and venous thrombosis, as well as bleeding. In addition to the different therapeutic strategies available,
- Antiplatelet therapy for aneurysmal subarachnoid haemorrhage
Cochrane Systematic Reviews, 17-Oct-2007
Secondary ischaemia is a frequent cause of poor outcome in patients with aneurysmal subarachnoid haemorrhage (SAH). Besides vasospasm, platelet aggregation seems to play a role in the pathogenesis of secondary ischaemia. Experimental studies have suggeste
- Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy
Cochrane Systematic Reviews, 21-Jul-2003
Antiplatelet drugs are effective and safe in a wide variety of patients at high risk of vascular ischaemic events. Among patients undergoing vascular surgical procedures, these agents significantly reduce the risk of graft or native vessel occlusion. In t
